JP2019530656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530656A5 JP2019530656A5 JP2019511707A JP2019511707A JP2019530656A5 JP 2019530656 A5 JP2019530656 A5 JP 2019530656A5 JP 2019511707 A JP2019511707 A JP 2019511707A JP 2019511707 A JP2019511707 A JP 2019511707A JP 2019530656 A5 JP2019530656 A5 JP 2019530656A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- och
- optionally substituted
- absent
- terminal nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 55
- 239000002773 nucleotide Substances 0.000 claims 30
- 125000003729 nucleotide group Chemical group 0.000 claims 28
- 239000002777 nucleoside Substances 0.000 claims 21
- -1 nucleoside phosphoramidite Chemical class 0.000 claims 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 18
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 108010024636 Glutathione Proteins 0.000 claims 9
- 229960003180 glutathione Drugs 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000006239 protecting group Chemical group 0.000 claims 8
- 108091081021 Sense strand Proteins 0.000 claims 7
- 230000000692 anti-sense effect Effects 0.000 claims 7
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 claims 6
- 108091030071 RNAI Proteins 0.000 claims 6
- 230000009368 gene silencing by RNA Effects 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 150000008300 phosphoramidites Chemical class 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229940124447 delivery agent Drugs 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052711 selenium Inorganic materials 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 125000003843 furanosyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 0 BC(C(*)C1O*)OC1OCP(*)(*)=O Chemical compound BC(C(*)C1O*)OC1OCP(*)(*)=O 0.000 description 8
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021180199A JP2022017481A (ja) | 2016-09-02 | 2021-11-04 | ４’－リン酸アナログ及びそれを含むオリゴヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383207P | 2016-09-02 | 2016-09-02 | |
| US62/383,207 | 2016-09-02 | ||
| US201662393401P | 2016-09-12 | 2016-09-12 | |
| US62/393,401 | 2016-09-12 | ||
| PCT/US2017/049909 WO2018045317A1 (en) | 2016-09-02 | 2017-09-01 | 4'-phosphate analogs and oligonucleotides comprising the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021180199A Division JP2022017481A (ja) | 2016-09-02 | 2021-11-04 | ４’－リン酸アナログ及びそれを含むオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530656A JP2019530656A (ja) | 2019-10-24 |
| JP2019530656A5 true JP2019530656A5 (enExample) | 2020-04-09 |
| JP6978099B2 JP6978099B2 (ja) | 2021-12-08 |
Family
ID=61301649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511707A Active JP6978099B2 (ja) | 2016-09-02 | 2017-09-01 | ４’−リン酸アナログ及びそれを含むオリゴヌクレオチド |
| JP2021180199A Withdrawn JP2022017481A (ja) | 2016-09-02 | 2021-11-04 | ４’－リン酸アナログ及びそれを含むオリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021180199A Withdrawn JP2022017481A (ja) | 2016-09-02 | 2021-11-04 | ４’－リン酸アナログ及びそれを含むオリゴヌクレオチド |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11414659B2 (enExample) |
| EP (2) | EP4101859A1 (enExample) |
| JP (2) | JP6978099B2 (enExample) |
| KR (2) | KR102493872B1 (enExample) |
| CN (1) | CN110072530B (enExample) |
| AU (1) | AU2017321892A1 (enExample) |
| CA (1) | CA3033756A1 (enExample) |
| DK (1) | DK3506909T3 (enExample) |
| ES (1) | ES2924806T3 (enExample) |
| HU (1) | HUE059718T2 (enExample) |
| IL (2) | IL264887B (enExample) |
| MX (1) | MX2019002339A (enExample) |
| PL (1) | PL3506909T3 (enExample) |
| PT (1) | PT3506909T (enExample) |
| WO (1) | WO2018045317A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015023275B1 (pt) * | 2013-03-15 | 2022-06-21 | Board Of Regents, The University Of Texas System | Método in vitro de detecção de biomarcador de câncer |
| EP3691657A4 (en) | 2017-10-04 | 2021-07-21 | Avidity Biosciences, Inc. | NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
| KR20200109311A (ko) | 2018-01-16 | 2020-09-22 | 다이서나 파마수이티컬, 인크. | Aldh2 발현을 억제하기 위한 조성물 및 방법 |
| JP2021520355A (ja) | 2018-04-13 | 2021-08-19 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｔｍ上昇ヌクレオチドで修飾された二本鎖核酸阻害剤分子 |
| WO2020123083A1 (en) * | 2018-12-12 | 2020-06-18 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules containing a triloop |
| SG11202106857VA (en) * | 2018-12-28 | 2021-07-29 | Dicerna Pharmaceuticals Inc | Compositions and methods for inhibiting hmgb1 expression |
| BR112021018739A2 (pt) | 2019-03-29 | 2022-05-03 | Dicerna Pharmaceuticals Inc | Composições e métodos para o tratamento de doenças ou distúrbios associados a kras |
| BR112021019793A2 (pt) | 2019-04-04 | 2021-12-07 | Dicerna Pharmaceuticals Inc | Composições e métodos para inibir expressão de gene no sistema nervoso central |
| AU2020268798A1 (en) * | 2019-05-03 | 2021-11-04 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| AU2020279101B2 (en) | 2019-05-17 | 2025-07-24 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
| CN114375296A (zh) | 2019-06-06 | 2022-04-19 | 艾维迪提生物科学公司 | 核酸多肽组合物及其用途 |
| MX2022008738A (es) * | 2020-01-15 | 2022-09-23 | Dicerna Pharmaceuticals Inc | Acidos nucleicos de fosfonato de 4'-o-metileno y analogos de estos. |
| PE20221578A1 (es) | 2020-03-06 | 2022-10-06 | Aligos Therapeutics Inc | Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas |
| US20230287425A1 (en) | 2020-03-18 | 2023-09-14 | Dicerna Pharmacuticals Inc. | Compositions and methods for inhibiting angptl3 expression |
| AU2021251249A1 (en) | 2020-04-10 | 2022-11-10 | Aligos Therapeutics, Inc. | Short interfering nucleic acid (siNA) molecules and uses thereof for coronavirus diseases |
| TW202221120A (zh) | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | 用於治療代謝症候群之組成物及方法 |
| CA3190481A1 (en) | 2020-08-04 | 2022-02-10 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting plp1 expression |
| KR20230061389A (ko) | 2020-08-04 | 2023-05-08 | 다이서나 파마수이티컬, 인크. | 올리고뉴클레오티드의 전신 전달 |
| US12435336B2 (en) | 2020-08-05 | 2025-10-07 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting LPA expression |
| TW202221122A (zh) | 2020-08-05 | 2022-06-01 | 瑞士商赫孚孟拉羅股份公司 | Ｂ型肝炎患者之寡核苷酸治療 |
| EP4225919A1 (en) | 2020-10-08 | 2023-08-16 | Dicerna Pharmaceuticals, Inc. | Selective delivery of oligonucleotides to glial cells |
| PE20250400A1 (es) | 2021-04-12 | 2025-02-11 | Dicerna Pharmaceuticals Inc | Composiciones y metodos para inhibir cetohexoquinasa |
| CA3209418A1 (en) | 2021-04-14 | 2022-10-20 | Utsav SAXENA | Compositions and methods for modulating pnpla3 expression |
| WO2022223515A2 (en) | 2021-04-19 | 2022-10-27 | Novo Nordisk A/S | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
| EP4347820A1 (en) | 2021-05-28 | 2024-04-10 | Novo Nordisk A/S | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression |
| EP4359530A1 (en) | 2021-06-24 | 2024-05-01 | Eli Lilly and Company | Novel rna therapeutics and uses thereof |
| US12465647B2 (en) | 2021-08-05 | 2025-11-11 | Sanegene Bio Usa Inc. | 1′-alkyl modified ribose derivatives and methods of use |
| EP4392556A1 (en) | 2021-08-25 | 2024-07-03 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting ?lpha-1 antitrypsin expression |
| EP4399217A2 (en) | 2021-09-08 | 2024-07-17 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| CN118234862A (zh) | 2021-09-08 | 2024-06-21 | 阿利戈斯治疗公司 | 经修饰的短干扰核酸分子(siNA)及其用途 |
| EP4405368A1 (en) | 2021-09-22 | 2024-07-31 | Sanegene Bio USA Inc. | 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides |
| EP4413015A1 (en) | 2021-10-05 | 2024-08-14 | Sanegene Bio USA Inc. | Polyhydroxylated cyclopentane derivatives and methods of use |
| JP2024543195A (ja) | 2021-12-01 | 2024-11-19 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ａｐｏｃ３発現を調節するための組成物及び方法 |
| EP4201947A1 (en) | 2021-12-22 | 2023-06-28 | F. Hoffmann-La Roche AG | Process for the backbone deprotection of oligonucleotides containing a terminal alkyl phosphonate group |
| WO2023131170A1 (zh) * | 2022-01-05 | 2023-07-13 | 大睿生物医药科技(上海)有限公司 | 具有核苷酸类似物的双链rna |
| US20230346819A1 (en) | 2022-02-22 | 2023-11-02 | Sanegene Bio Usa Inc. | 5'-modified carbocyclic ribonucleotide derivatives and methods of use |
| EP4493568A1 (en) | 2022-03-18 | 2025-01-22 | Dicerna Pharmaceuticals, Inc. | Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide |
| US20230374522A1 (en) | 2022-04-15 | 2023-11-23 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating scap activity |
| CN119183476A (zh) * | 2022-04-26 | 2024-12-24 | 上海拓界生物医药科技有限公司 | 氘代化学修饰和包含其的寡核苷酸 |
| US20240002857A1 (en) | 2022-05-09 | 2024-01-04 | Sanegene Bio Usa Inc. | Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof |
| CN119173631A (zh) | 2022-05-12 | 2024-12-20 | 迪克纳制药公司 | 用于抑制mapt表达的组合物和方法 |
| IL316843A (en) | 2022-05-13 | 2025-01-01 | Dicerna Pharmaceuticals Inc | Compounds and methods for inhibiting SNCA deactivation |
| TWI868755B (zh) | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| EP4555088A1 (en) | 2022-07-11 | 2025-05-21 | Sanegene Bio USA Inc. | Optimized 2'- modified ribose derivatives and methods of use |
| KR20250046303A (ko) | 2022-08-05 | 2025-04-02 | 사네진 바이오 유에스에이 인크. | 안지오텐시노겐 (agt)을 표적화하는 이중 가닥 rna 및 그의 사용 방법 |
| WO2024040041A1 (en) | 2022-08-15 | 2024-02-22 | Dicerna Pharmaceuticals, Inc. | Regulation of activity of rnai molecules |
| TW202430192A (zh) | 2022-10-11 | 2024-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療nash之劑量方案 |
| TW202430191A (zh) | 2022-10-11 | 2024-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療伴有晚期纖維化及/或硬化之nash的方法 |
| KR20250088573A (ko) | 2022-10-14 | 2025-06-17 | 사네진 바이오 유에스에이 인크. | C3을 표적화하는 소형 간섭 rna 및 그의 용도 |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
| WO2024112865A1 (en) | 2022-11-23 | 2024-05-30 | Eli Lilly And Company | Method of synthesizing 4'-phosphate analog nucleotide phosphoramidite |
| JP2025541262A (ja) * | 2022-12-13 | 2025-12-18 | 上海拓界生物医薬科技有限公司 | 親油性モノマーを含むオリゴヌクレオチド及びその非肝臓送達における使用 |
| WO2024137590A2 (en) | 2022-12-19 | 2024-06-27 | Sanegene Bio Usa Inc. | Small interfering rna targeting cfb and uses thereof |
| AR131419A1 (es) | 2022-12-21 | 2025-03-19 | Lilly Co Eli | TERAPÉUTICOS NOVEDOSOS DE iARN DE FAS Y USOS DE ESTOS |
| WO2024138105A1 (en) | 2022-12-23 | 2024-06-27 | Eli Lilly And Company | Novel rna therapeutics and uses thereof |
| CN120457209A (zh) | 2022-12-23 | 2025-08-08 | 伊莱利利公司 | 新型rna治疗剂及其用途 |
| CN118271378A (zh) * | 2022-12-29 | 2024-07-02 | 中国科学院深圳先进技术研究院 | 一种糖环修饰的核苷亚磷酰胺单体及其制备方法和应用 |
| US20240309383A1 (en) | 2023-02-24 | 2024-09-19 | Suzhou Sanegene Bio Inc. | Small interfering rna targeting hbv and uses thereof |
| WO2024186673A2 (en) | 2023-03-03 | 2024-09-12 | Sanegene Bio Usa Inc. | Small interfering rna targeting apoc3 and uses thereof |
| KR20250174651A (ko) * | 2023-04-06 | 2025-12-12 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 5'-포스포네이트 변형 뉴클레오시드 유사체 및 이로부터 제조된 올리고뉴클레오티드 |
| WO2024227059A2 (en) | 2023-04-27 | 2024-10-31 | Aligos Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same |
| TWI904659B (zh) | 2023-05-08 | 2025-11-11 | 美商美國禮來大藥廠 | 使用環磷核苷的寡核苷酸合成法 |
| WO2024233864A2 (en) | 2023-05-10 | 2024-11-14 | Dicerna Pharmaceuticals, Inc. | Galnac-conjugated rnai oligonucleotides |
| KR20260018067A (ko) | 2023-05-26 | 2026-02-06 | 일라이 릴리 앤드 캄파니 | 신규 SCN10A RNAi 작용제 및 그의 용도 |
| CN121079106A (zh) | 2023-05-31 | 2025-12-05 | 上海拓界生物医药科技有限公司 | 一种靶向LPA的dsRNA及其应用 |
| WO2024259190A2 (en) * | 2023-06-15 | 2024-12-19 | Alnylam Pharmaceuticals, Inc. | 5'-modified monomers, oligonucleotides and double-stranded rnas |
| WO2024263915A2 (en) | 2023-06-21 | 2024-12-26 | Sanegene Bio Usa Inc. | Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereof |
| US20250064939A1 (en) | 2023-07-24 | 2025-02-27 | Sanegene Bio Usa Inc. | Lipid-based enhancement agent for rna delivery and therapy |
| IL326017A (en) | 2023-07-28 | 2026-03-01 | Novo Nordisk As | Compositions and methods for expressing programmed death ligand receptor (PD-L1) |
| AU2024325721A1 (en) * | 2023-08-17 | 2026-02-26 | Adarx Pharmaceuticals, Inc. | Oligonucleotides containing a ligand at a nucleobase, 2' position, or 3' position |
| WO2025054459A1 (en) | 2023-09-08 | 2025-03-13 | Dicerna Pharmaceuticals, Inc. | Rnai oligonucleotide conjugates |
| WO2025228441A2 (en) | 2024-04-30 | 2025-11-06 | Sanegene Bio Usa Inc. | Small interfering rna targeting inhbe and uses thereof |
| WO2025250605A1 (en) | 2024-05-31 | 2025-12-04 | Eli Lilly And Company | Acvr2a and acvr2b rna interference agents |
| WO2025259992A1 (en) * | 2024-06-14 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | 5'-modified monomers, oligonucleotides and double-stranded rnas |
| WO2025260011A1 (en) * | 2024-06-14 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | 5'-modified monomers, oligonucleotides and double-stranded rnas |
| WO2025264952A2 (en) | 2024-06-21 | 2025-12-26 | Eli Lilly And Company | Novel rna therapeutics and uses thereof |
| WO2025264948A2 (en) | 2024-06-21 | 2025-12-26 | Eli Lilly And Company | Inhbe rna interference agents |
| WO2026006109A2 (en) | 2024-06-24 | 2026-01-02 | Eli Lilly And Company | Novel rna therapeutics and uses thereof |
| WO2026017140A2 (en) | 2024-07-18 | 2026-01-22 | Sanegene Bio Usa Inc. | Small interfering rna targeting fxi and uses thereof |
| WO2026030418A2 (en) | 2024-07-31 | 2026-02-05 | Eli Lilly And Company | Oligonucleotide synthesis using cyclic-phosphorous nucleosides |
| WO2026041067A2 (en) | 2024-08-20 | 2026-02-26 | Sanegene Bio Usa Inc. | Small interfering rna targeting myostatin (mstn) and uses thereof |
| US20260055414A1 (en) | 2024-08-21 | 2026-02-26 | Novo Nordisk A/S | Compositions and methods for inhibiting xdh expression |
| WO2026046411A1 (en) | 2024-09-02 | 2026-03-05 | Sanegene Bio Usa Inc. | Small interfering rna targeting plasminogen (plg) and uses thereof |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
| US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
| US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
| JPH03503894A (ja) | 1988-03-25 | 1991-08-29 | ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション | オリゴヌクレオチド ｎ‐アルキルホスホラミデート |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
| CA2297294C (en) * | 1989-05-15 | 2005-11-08 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxymethylpurine/pyrimidine derivatives |
| US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
| US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US6001840A (en) | 1990-03-06 | 1999-12-14 | Southern Research Institute | Methods of treatment of viral infections using carbocyclic deoxyguanosine analogs |
| US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
| US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US5998603A (en) * | 1994-09-29 | 1999-12-07 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analogs, and oligomers thereof |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| MY107332A (en) | 1990-08-03 | 1995-11-30 | Sterling Drug Inc | Compounds and methods for inhibiting gene expression. |
| US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
| US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
| US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
| JPH06505704A (ja) | 1990-09-20 | 1994-06-30 | ギリアド サイエンシズ，インコーポレイテッド | 改変ヌクレオシド間結合 |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
| US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| HU9501974D0 (en) | 1993-03-31 | 1995-09-28 | Sterling Winthrop Inc | Oligonucleotides with amide linkages replacing phosphodiester linkages |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
| US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
| US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| AU733310C (en) | 1997-05-14 | 2001-11-29 | University Of British Columbia, The | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| JP4236812B2 (ja) * | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| DE69941447D1 (de) | 1998-01-05 | 2009-11-05 | Univ Washington | Erhöhter transport unter benutzung membranzerstörender stoffe |
| US7737108B1 (en) | 2000-01-07 | 2010-06-15 | University Of Washington | Enhanced transport using membrane disruptive agents |
| JP2004501955A (ja) | 2000-06-30 | 2004-01-22 | アイネックス ファーマシューティカルズ コーポレイション | リポソーム抗新生物薬剤およびその使用 |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20030190626A1 (en) * | 2002-04-09 | 2003-10-09 | Vasulinga Ravikumar | Phosphorothioate monoester modified oligomers |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| EA014685B1 (ru) * | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| EP1750673B1 (en) | 2004-05-17 | 2009-12-02 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| US7718193B2 (en) | 2006-03-16 | 2010-05-18 | University Of Washington | Temperature- and pH-responsive polymer compositions |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
| WO2009018332A1 (en) | 2007-08-01 | 2009-02-05 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand |
| CA2972694C (en) | 2008-05-13 | 2020-02-11 | University Of Washington | Diblock copolymers and polynucleotide complexes thereof for delivery into cells |
| AU2009246321A1 (en) | 2008-05-13 | 2009-11-19 | Phaserx, Inc. | Polymeric carrier |
| KR20110020804A (ko) | 2008-05-13 | 2011-03-03 | 유니버시티 오브 워싱톤 | 치료제의 세포내 전달을 위한 미셀 |
| WO2009140423A2 (en) | 2008-05-13 | 2009-11-19 | University Of Washington | Targeted polymer bioconjugates |
| EP2285853B1 (en) | 2008-05-13 | 2013-02-27 | University of Washington | Micellic assemblies |
| JP2012500793A (ja) | 2008-08-22 | 2012-01-12 | ユニヴァーシティ オブ ワシントン | 細胞内デリバリーのための異種性ポリマーミセル |
| DK2341943T3 (en) | 2008-09-22 | 2019-02-25 | Dicerna Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| US20110281934A1 (en) | 2008-11-06 | 2011-11-17 | Phaserx, Inc. | Micelles of hydrophilically shielded membrane-destabilizing copolymers |
| MX2011004242A (es) | 2008-11-06 | 2011-07-20 | Univ Washington | Copolimeros multibloque. |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| KR101728655B1 (ko) | 2008-12-18 | 2017-04-19 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2011005860A2 (en) * | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| JP2013504585A (ja) * | 2009-09-09 | 2013-02-07 | セントローズ， エルエルシー | 細胞外標的化薬物複合体 |
| US9102938B2 (en) * | 2010-04-01 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | 2′ and 5′ modified monomers and oligonucleotides |
| WO2011133871A2 (en) * | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| EP2601204B1 (en) | 2010-04-28 | 2016-09-07 | Ionis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| CA3131967A1 (en) | 2010-12-29 | 2012-07-05 | F. Hoffman-La Roche Ag | Small molecule conjugates for intracellular delivery of nucleic acids |
| AU2013315543A1 (en) | 2012-09-14 | 2015-04-09 | Dicerna Pharmaceuticals, Inc. | Methods and compostions for the specific inhibition of MYC by double-stranded RNA |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| CN105142614A (zh) | 2013-03-14 | 2015-12-09 | 迪克纳制药公司 | 用于配制阴离子试剂的方法 |
| US10119136B2 (en) * | 2014-01-09 | 2018-11-06 | Alnylam Pharmaceuticals, Inc. | RNAi agents modified at the 4′-C position |
| CN107428792B (zh) | 2014-12-15 | 2023-01-24 | 埃默里大学 | 用于治疗乙型肝炎病毒的磷酰胺 |
| DK3569711T3 (da) | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| EP3067369A1 (en) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the treatment of anti-angiogenic resistant cancer |
| US10087209B2 (en) | 2015-04-28 | 2018-10-02 | Ku Leuven Research & Development | Antiviral compounds, a process for their preparation, and their use for treating viral infections |
| JP7249080B2 (ja) * | 2016-08-23 | 2023-03-30 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
-
2017
- 2017-09-01 HU HUE17847638A patent/HUE059718T2/hu unknown
- 2017-09-01 PL PL17847638.8T patent/PL3506909T3/pl unknown
- 2017-09-01 JP JP2019511707A patent/JP6978099B2/ja active Active
- 2017-09-01 CN CN201780068124.5A patent/CN110072530B/zh active Active
- 2017-09-01 ES ES17847638T patent/ES2924806T3/es active Active
- 2017-09-01 AU AU2017321892A patent/AU2017321892A1/en not_active Abandoned
- 2017-09-01 US US16/328,546 patent/US11414659B2/en active Active
- 2017-09-01 DK DK17847638.8T patent/DK3506909T3/da active
- 2017-09-01 WO PCT/US2017/049909 patent/WO2018045317A1/en not_active Ceased
- 2017-09-01 MX MX2019002339A patent/MX2019002339A/es unknown
- 2017-09-01 CA CA3033756A patent/CA3033756A1/en active Pending
- 2017-09-01 PT PT178476388T patent/PT3506909T/pt unknown
- 2017-09-01 EP EP22175611.7A patent/EP4101859A1/en active Pending
- 2017-09-01 KR KR1020227000736A patent/KR102493872B1/ko active Active
- 2017-09-01 EP EP17847638.8A patent/EP3506909B1/en active Active
- 2017-09-01 KR KR1020197008956A patent/KR102350647B1/ko active Active
-
2019
- 2019-02-18 IL IL264887A patent/IL264887B/en unknown
-
2021
- 2021-11-04 JP JP2021180199A patent/JP2022017481A/ja not_active Withdrawn
- 2021-11-25 IL IL288418A patent/IL288418A/en unknown
-
2022
- 2022-07-07 US US17/859,781 patent/US12037586B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530656A5 (enExample) | ||
| US20230101227A1 (en) | Compositions comprising reversibly modified oligonucleotides and uses thereof | |
| ES2924806T3 (es) | Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo | |
| US12415828B2 (en) | Modified oligonucleotides and methods for their synthesis | |
| WO2021071858A1 (en) | Oligonucleotide compositions and methods of use thereof | |
| JP2019526555A5 (enExample) | ||
| JP2021503941A5 (enExample) | ||
| JP2022513111A5 (enExample) | ||
| WO2015093495A1 (ja) | ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子 | |
| US20180223280A1 (en) | Nucleic acid complex | |
| AU2016382055C1 (en) | Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof | |
| EP3366774A1 (en) | Nucleic acid complex having at least one bulge structure | |
| WO2026073042A1 (en) | Oligonucleotide compositions and methods thereof | |
| WO2026073043A2 (en) | Oligonucleotide compositions and methods thereof | |
| WO2023282345A1 (ja) | 腎毒性軽減剤 | |
| WO2025072879A1 (en) | Oligonucleotide compositions and methods thereof | |
| WO2023282344A1 (ja) | 腎毒性軽減剤 | |
| US10337009B2 (en) | Single-stranded nucleic acid molecule for inhibiting TGF-β1 expression | |
| NZ750307B2 (en) | Compositions comprising reversibly modified oligonucleotides and uses thereof |